Side-by-side · Research reference

AOD-9604vsIGF-1 LR3

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/47 cited

BAnimal-StrongHUMAN-REVIEWED10/58 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2000

~30 minHalf-life

SQ · Abdomen · Daily fasted

IGF-1 LR3

IGF-1 Analogue · Research

3–10×Potency vs IGF-I

Low IGFBPBinding affinity

ResearchStatus

Research only · SQ typical in animal models

01Mechanism of Action

Parameter

AOD-9604

IGF-1 LR3

Primary target

β3-adrenergic receptor (proposed)Ng 2000

IGF-1 receptor (IGF-1R)McTavish 2009

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000

IGF-1R → IRS-1 → PI3K/Akt → Cell proliferation, protein synthesis, anti-apoptosisMuhlbradt 2009

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Enhanced cell proliferation, muscle anabolism, inhibition of apoptosis, increased telomerase activity

Feedback intact?

No GH-axis or IGF-1 feedback

No — exogenous IGF analogue bypasses GH-mediated regulation

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000

Synthetic 83-AA analogue: 13-AA N-terminal extension + Arg substitution at position 3

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

IGF-1 LR3

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

—

Frequency

Once daily, fasted

—

Lower / starter dose

150 mcg / day

—

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2000

Animal / in vitro only

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

—

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

—

Half-life

~30 min plasma

—

Research dose (animal models)

—

Variable by protocol and species

In vivo murine atherosclerosis studies used sustained delivery.

In vitro typical concentration

—

10–1000 ng/mLThomas 2007

Dose-dependent effects on follicle growth and estradiol production.

Half-maximal stimulation

—

0.6 nM LR3 vs 1.5 nM native IGF-1Price 2004

2.5-fold greater potency in lung fibroblast proliferation.

Human use

—

Not FDA-approved; no published human trials

03Metabolic / Fat Loss Evidence

Parameter

AOD-9604

IGF-1 LR3

Mechanism

—

IGF-1R activation → lipolytic signaling; secondary to anabolic effects

Direct lipolytic evidence

—

Minimal — primarily anabolic/anti-apoptotic in literature

Atherosclerotic plaque effects

—

Reduced stenosis and core size in ApoE-KO micevon 2011

Plaque stabilization via vSMC phenotype modulation, not direct fat loss.

Human data

—

None published

04Side Effects & Safety

Parameter

AOD-9604

IGF-1 LR3

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

—

Pregnancy / OB

Avoid

—

Hypoglycemia risk

—

Theoretical — IGF-1 analogues can lower blood glucose

Excessive cell proliferation

—

Mitogenic signaling; theoretical tumor promotion risk

Telomerase activation

—

2–10-fold increase in prostate cancer cells (PC-3, DU-145, LAPC-4)Wetterau 2003

Critically involved in cancer cell immortalization.

Oocyte degeneration

—

Increased oocyte degeneration at high doses (≥1000 ng/mL) in bovine folliclesThomas 2007

Unregulated anabolism

—

Bypasses physiological GH/IGF-1 feedback; no pulsatility control

Unknown human safety profile

—

No published human trials; safety data absent

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

IGF-1 LR3

·Active malignancy or history of cancer
·Not approved for human use

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

IGF-1 LR3

·Diabetes or glucose intolerance
·Family history of cancer

05Administration Protocol

Parameter

AOD-9604

IGF-1 LR3

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

IGF-1 LR3 is not FDA-approved for human use. All administration data derives from animal or in vitro studies.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Subcutaneous or intraperitoneal injection in animal models. In vitro: added directly to culture medium at concentrations of 10–1000 ng/mL.Thomas 2007

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

Lyophilised powder reconstituted in sterile water or buffered saline per manufacturer protocol. Store at 2–8 °C after reconstitution.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Enhanced stability vs native IGF-1 due to reduced IGFBP binding; exact half-life in vivo not fully characterized in humans.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

IGF-1 LR3

+ GHRP-6

Multi-pathway

View GHRP-6 →

GHRP-6 stimulates endogenous GH release, which drives hepatic IGF-1 synthesis. IGF-1 LR3 provides exogenous, IGFBP-resistant IGF signaling. Combining upstream GH stimulation with downstream IGF receptor activation creates a dual-pathway anabolic effect. However, this bypasses natural feedback and carries compounded mitogenic risk.

GHRP-6: 100–200 mcg SQ · 2–3× daily
IGF-1 LR3: Research doses variable · post-workout typical in animal models
Note: Research context only — no human protocols exist
Primary benefit: Theoretical maximal anabolic signaling (GH + IGF axes)

+ Ipamorelin

Multi-pathway

View Ipamorelin →

Ipamorelin (selective GHRP) stimulates pulsatile GH release without cortisol/prolactin elevation. IGF-1 LR3 directly activates IGF-1R independent of GH. This stack targets both upstream (GH secretion) and downstream (IGF receptor) nodes but eliminates physiological feedback, raising safety concerns around unchecked proliferation.

Ipamorelin: 200–300 mcg SQ · evening
IGF-1 LR3: Research doses only · timing variable
Caution: No human data; animal/in vitro only
Primary benefit: Dual-axis anabolic signaling (theoretical)